Shibeikang Biomedical

Company Profile

Employee Corner

Shibeikang's First-in-Class Mucolytic Drug SBK001 Achieves Success in Phase II Clinical Trial

Recently, the Phase II clinical trial of SBK001 Injection, a global first‑in‑class Category 1 new drug independently developed by Chengdu Shibeikang Biomedical ...

SBK’s SBK007 Research Abstract Accepted for Presentation（EAACI Congress 2026）

On March 12, 2026, the latest research findings>EAACI 2026: A Leading Global Conference in Allergy and ImmunologyOrganized by the European Academy of Allergy an...

The sbk002 Study Abstract from SBK Has Been Accepted for Presentation at the 2026 American College o...

On December 16, 2025, the American College of Cardiology officially accepted the abstract detailing clinical research results of sbk002 (Becondogrel), a next-ge...

Latest Research Findings on Next-Generation Antiplatelet Drug SBK019 Published in Circulation Resear...

On December 5, 2025, the top-tier cardiovascular journal Circulation Research (Volume 137, Number 12) officially published the preclinical research findings of ...

SBK Showcases Multiple Innovations at AHA 2025 and ACRE-cnAHA 2025 Symposium

The American Heart Association Scientific Sessions 2025 (AHA 2025) took place November 7–10 in New Orleans, Louisiana. As style="text-align:center;"> Keynote S...

上一页12345678...1112下一页